These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33130701)

  • 1. [Late-Onset Acute Pneumonitis Caused by Pembrolizumab Used to Treat Postoperative Recurrence of Squamous Cell Carcinoma-A Case Report].
    Kamiyoshihara M; Yoshikawa R; Igai H; Matsuura N; Yazawa T; Ohsawa F
    Gan To Kagaku Ryoho; 2020 Sep; 47(9):1363-1365. PubMed ID: 33130701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recurrent Postoperative Lung Cancer with Tumor Shrinkage after Discontinuation of Pembrolizumab-A Case Report].
    Kamiyoshihara M; Igai H; Matsuura N; Ohsawa F; Numajiri K
    Gan To Kagaku Ryoho; 2022 Jan; 49(1):67-69. PubMed ID: 35046365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A Case of Squamous Cell Lung Cancer in an Elderly Patient with Low PD-L1 Expression Effectively Treated with Nab-Paclitaxel(Nab-PTX)plus Carboplatin (CBDCA)plus Pembrolizumab for a Recurrence after Operation].
    Sakaguchi K; Kosaka M; Yamazaki Y
    Gan To Kagaku Ryoho; 2020 May; 47(5):819-821. PubMed ID: 32408327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
    Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
    BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Docetaxel and Ramucirumab Combination Chemotherapy after Nivolumab Treatment for Pretreated Pulmonary Squamous Cell Carcinoma-A Successful Case].
    Kamiyoshihara M; Yazawa T; Igai H; Matsuura N; Ohsawa F; Iwashita H
    Gan To Kagaku Ryoho; 2021 Feb; 48(2):211-213. PubMed ID: 33597361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late-onset programmed cell death protein-1 inhibitor-induced pneumonitis after cessation of nivolumab or pembrolizumab in patients with advanced non-small cell lung cancer: a case series.
    Kimura H; Sone T; Araya T; Murata A; Yamamura K; Ohkura N; Hara J; Abo M; Kasahara K
    Transl Lung Cancer Res; 2021 Mar; 10(3):1576-1581. PubMed ID: 33889531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
    Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
    Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review].
    Chen YL; Zhao J; Jia R; Wang HY; Zheng J; Bai CQ; Wang MZ; Xu JM
    Zhonghua Jie He He Hu Xi Za Zhi; 2017 Oct; 40(10):736-743. PubMed ID: 29050127
    [No Abstract]   [Full Text] [Related]  

  • 9. A case of solitary paraaortic lymph node recurrence of lung squamous cell carcinoma after resection.
    Kajiura K; Taniguchi H; Ishimine T; Nakamura K; Ishigaki M; Fukumoto T
    J Med Invest; 2018; 65(3.4):283-285. PubMed ID: 30282874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Alectinib for an Octogenarian Patient with Poor Performance Status and ALK Fusion Gene-Positive Lung Cancer-A Case Report].
    Kamiyoshihara M; Igai H; Matsuura N; Yazawa T; Ohsawa F
    Gan To Kagaku Ryoho; 2021 Aug; 48(8):1053-1055. PubMed ID: 34404075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Complete response by S-1 with multiple pulmonary metastases 4 years after lung resection-a case report].
    Sugiura Y; Takeuchi K; Kakizaki T; Kaseda S
    Gan To Kagaku Ryoho; 2009 Dec; 36(13):2611-4. PubMed ID: 20009464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete response of squamous cell carcinoma of the lung following treatment with pembrolizumab in an elderly patient: A case report.
    Takeuchi E; Okamoto Y; Takahashi N; Morizumi S; Toyoda Y; Kuroda N; Yorita K
    Thorac Cancer; 2021 Jan; 12(2):259-263. PubMed ID: 33174378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early presentation of pembrolizumab-associated pneumonitis.
    Christy J; Rafae A; Kandah E; Kunadi A
    BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34266820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US.
    Insinga RP; Vanness DJ; Feliciano JL; Vandormael K; Traore S; Ejzykowicz F; Burke T
    Curr Med Res Opin; 2019 Jul; 35(7):1241-1256. PubMed ID: 30649973
    [No Abstract]   [Full Text] [Related]  

  • 15. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
    Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
    J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
    Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
    Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
    Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY
    J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.
    Imai H; Wasamoto S; Yamaguchi O; Suzuki K; Sugiyama T; Uchino J; Minemura H; Osaki T; Ishii H; Umeda Y; Mori K; Kotake M; Kagamu H; Morozumi N; Taniguchi H; Kasai T; Minato K; Kaira K
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):457-466. PubMed ID: 31853661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
    Langer CJ; Gadgeel SM; Borghaei H; Papadimitrakopoulou VA; Patnaik A; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Jalal SI; Panwalkar A; Yang JC; Gubens M; Sequist LV; Awad MM; Fiore J; Ge Y; Raftopoulos H; Gandhi L;
    Lancet Oncol; 2016 Nov; 17(11):1497-1508. PubMed ID: 27745820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.